48Hour Discovery

2:00 PM - 4:00 PM (EDT), Tuesday, June 6, 2023 ・ North Lobby
48Hour Discovery (48HD) is a leading peptide-based platform accelerating discovery of novel molecules for the delivery of therapeutic payloads, with a focus on bringing targeted radiopharmaceuticals to market faster than ever before.

48HD is driven by chemically modified billion-scale phage libraries and high throughput next-generation sequencing analysis to identify cyclic peptide ligands with high affinity and specificity. The 48HD platform has been validated through over 20 partnerships, including public projects with industry leaders like Merck and Fusion Pharmaceuticals.

In the last 12 months, 48HD has:
-Secured roughly USD $2M in revenue,
-Added peptide drug expert Dr. Tomi Sawyer (ex-Merck Global Chemistry & Peptide Drug Hunter) to their Board of Directors, -Added oncology and radiopharma expert Dr. Frank Wuest (Kipnes Chair in Radiopharmaceutical Science / AHFMR Senior Scholar) to their SAB,
-Won the Startup TNT Investment Summit VI (USD $200K),
-Partnered with a Korean AI company on 48HD’s internal program driving a USD $3M valuation for a single asset,
-Gained full assignment of patent portfolio (5 patents) from the University of Alberta,
-Initiated platform scale-up enabling parallel screening of many targets.
Placeholder Photo
Vice President, Research and Development
48Hour Discovery